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categorized regarding the speciﬁcs of the type of data requested.
Using a comparative framework to examine the recommenda-
tions of CDR and NICE, we describe the frequency of the dif-
ferent types of data recommended for collection post-launch to
highlight trends across jurisdictions RESULTS: Thirty-four of 64
CDR submissions recommended ‘no listing’, 17 ‘list with crite-
ria’, and 13 ‘list or list in similar manner as other drugs in the
same category’. Of the 64 appraisals, 41 were recommended to
conduct further research to either collect speciﬁc items of data
(n = 28), conduct subgroup analysis (n = 13), or collect data
using a more appropriate study design (n = 19). The most com-
monly requested item was long-term adverse events or safety
data (16/28), and this observation is consistent with the fact that,
to date, most post-launch studies are safety surveillance studies.
In addition 11 of 28 recommended the collection of clinically
important outcomes, long-term effectiveness (7/28). Similarly, 41
of 48 NICE appraisals recommended further research to collect
real-world data, including treatment pathways, effectiveness, and
long-term effectiveness or adverse events. CONCLUSION: This
review suggests that recommendations for post-launch research
from CDR and NICE appear to be similar. This highlights the
inherent weakness of regulatory trials as a piece of evidence in
informing reimbursement decisions.
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OBJECTIVE: To assess lifetime cost-effectiveness of glatiramer
acetate (GA) compared to natalizumab (NZ) in patients diag-
nosed with relapsing-remitting multiple sclerosis (RRMS) in
the presence of long-term clinical evidence. METHODS: A
literature-based Markov model was developed with patients
transitioning through health-states based on Kurtzke expanded
disability status scale (EDSS). Patients in the model are21 years
of age with RRMS and start in any of the health-states at diag-
nosis. Patients with an EDSS score below 6.0 receive treatment.
Treatment effects for relapse and disease progression were
obtained from clinical trials and long-term clinical evidence
where available. Transition rates were estimated by applying a
percent reduction of treatment effects of therapies to natural
history rates of relapse and disease progression. Rates were
adjusted for treatment discontinuation and persistent NZ anti-
bodies. Patients incurred drug, other medical and lost worker
productivity costs. Patients on NZ incurred additional costs for
monitoring, diagnosis, and treatment of progressive multifocal
leukoencephalopathy (PML), a possible serious adverse event for
patients on NZ. Utility weights for each health-state were taken
from published utility assessments for people with RRMS. The
primary outcomes of the model were lifetime costs and quality-
adjusted life years (QALYs). Costs (2005US$) and outcomes
were discounted at 3% annually. RESULTS: The lifetime costs
per patient for GA were $430,242 and for NZ were $498,728.
QALYs during the lifetime of a patient on GA were 9.303 and
9.300 for a patient on NZ. The incremental cost per QALY for
patients on GA and NZ compared to symptomatic treatment
alone was $208,879 and $525,463 respectively. GA is cost-
saving when compared to NZ. PML had very little impact on
results. CONCLUSIONS: While incorporating all the long-term
clinical evidence, model results indicated that GA was both less
costly and more effective over a patient’s lifetime than NZ in
treating RRMS.
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OBJECTIVES: Public health care system in Paraguay is highly
centralized, compared to other Latin American sectors, and more
than half of the population relies on it in order to receive formal
treatment. The National Immunization Program (EPI) is not an
exemption, affecting the way local/departmental resources in
immunization are allocated, impacting on the effectiveness of
these investments. In addition, differences in population charac-
teristics among departments, in terms of health care behavior,
income and education, and the use of formal medicine patterns
by original ethnic groups might affect EPIxs effectiveness. The
goal of the paper is to identify how supply side characteristics
(ﬁnancial, managerial and immunization strategies) and demand
side factors impact on immunization coverage. METHODS: The
document proposes a sequential model, where local health
authorities intent to ﬁll the gap in immunization ﬁnancing and
managerial needs, based on the resources allocation and coverage
strategy deﬁned by the national health ministry, that leads the
Paraguayan immunization design. As a result, a logistic model
was implemented, where the likelihood of being vaccinated is
tested as a dependent variable, where geographical, educational
and ethnical barriers are checked. In addition, supply variables
related to ﬁnancing, coverage strategies and communicational
efforts are included. The study analyze data from the Integrated
National Household Survey (2001), complemented with a series
of immunization effectiveness indexes constructed based on man-
agement, ﬁnancing and vaccine provision criterion, distinguish-
ing among ﬁnancial sustainability, management effectiveness and
antigen supply volatility, collected from ofﬁcial sources and inter-
views with key personnel by region. RESULTS: Health care
policy variables were statistically signiﬁcant, showing the rel-
evance of social communication, measured in terms of physical,
monetary and human resources involved. CONCLUSION: The
paper shows the importance of socio-economic-cultural barriers
on the probability of being immunized, based on health behavior,
presence of formal health insurance, and main source of care
(hospital, traditional medicine, etc.).
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OBJECTIVES: To assess the generic cost-effectiveness of health
care. METHODS: We estimated the contribution of prevention
and medical care towards population health for infectious dis-
eases, cancers, and cardiovascular diseases. This contribution
was deﬁned as the difference between the current burden of
disease (BoD) and its counterfactual: a ‘null’ situation without
selected prevention (vaccinations, screening, and preventive
medication) and medical care, and accounting for the role of
other health determinants such as improvements in housing and
nutrition, and reduced smoking. The counterfactual was back-
calculated with use of historical data on incidence, survival,
mortality, and the prevalence of risk factors. The Global Burden
of Disease methodology was applied, combining incidence,
prevalence, mortality, and disability weights into multi-state
lifetables. If required, epidemiological estimates were made
internally consistent with advanced modelling techniques
(DISMOD2). The difference between the current BoD and the
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counterfactual was combined with cost of illness data to estimate
the generic cost-effectiveness of prevention and medical care for
the selected disease clusters. RESULTS: The total increase in
disability adjusted life expectancy due to prevention and medical
care was 5.3 years: 1.7 years for infectious diseases, 0.6 years for
cancers, and 3.1 years for cardiovascular diseases. This increase
was larger for females than for males: 6.3 years and 4.3 years,
respectively. The increase can be disentangled into an increase in
life expectancy of 3.9 years and 1.4 decrease in years lived with
disability. The average costs per DALY gained were 2,000 euro
for cardiovascular disease, 3,400 euro for infectious diseases, and
16,000 euro for cancers. CONCLUSION: For the selected
disease clusters, the average cost-effectiveness of health care is far
below current acceptable thresholds. We assessed the likely
health contribution of sociocultural and socioeconomic factors
as opposed to health care with help of the best available knowl-
edge, but many questions remain unanswered.
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OBJECTIVES: Public insurance for the poor (Medicaid) in the
United States often results in poor continuity of coverage due to
the phenomenon of “churning.” Churning occurs when individu-
als lose and regain coverage in a short period of time. Gaps occur
within the Medicaid program because of changes in family cir-
cumstances that make individuals ineligible for public insurance
or because of administrative complexity that result in failure to
renew coverage. The purpose of this study is to evaluate the
impact of insurance transitions on health care utilization among
the publicly insured non-elderly. METHODS: We used the
Medical Expenditure Panel Survey (MEPS) for years 2000–2004
for this study. MEPS provides monthly insurance status and
resource utilization. Additionally, MEPS contains detailed demo-
graphic, socioeconomic and health status information. We esti-
mated the number of transitions for an individual using monthly
insurance data. We estimated resource utilization using the total
number of inpatient hospitalizations, emergency room visits, out-
patient visits, and total number of prescriptions. Number of
inpatient hospitalization and emergency room visits were
modeled using zero-inﬂated negative binomial models, while out-
patient visits and prescription drugs were modeled using negative
binomial models. RESULTS: Our sample has 35,779 individuals,
of whom 10,754 had one transition into or out of Medicaid and
2,448 had more than one transition. We ﬁnd that individuals
with multiple transitions tend to have 46% more hospitalizations
and use the emergency room 13% more. However, these indi-
viduals have 37% lower prescription drug utilization and 12%
less outpatient physician visits relative to those who are continu-
ously insured by Medicaid. CONCLUSION: Utilization of emer-
gency and inpatient services were signiﬁcantly higher, while use
of outpatient care and prescription drugs was signiﬁcantly lower
for beneﬁciaries with interruption in Medicaid coverage. These
ﬁndings point to the need for further research to assess the
impact of churning in this population.
PHP22
THE GREEK PHARMACEUTICAL EXPENDITURE DATA:
EFFECTS OFTHE NATIONAL ACCOUNTS’ REVISION
Kousoulakou H1, Kyriopoulos J2
1Foundation for Economic and Industrial Research, Athens, Greece,
2National School of Public Health, Athens, Greece
OBJECTIVES: In September 2006, the National Statistical
Service of Greece revised the system of National Accounts. In this
framework, signiﬁcant increases took place in the data describing
the pharmaceutical market, the overall picture of which has
completely changed. The study aims to present these changes, as
well as highlight some remarkable (or even questionable) char-
acteristics of the revision. METHODS: Data from ofﬁcial sources
relating to pharmaceuticals’ production, external trade, expendi-
ture and sales were collected and analyzed, in an effort to
synthesize the overall picture of the pharmaceutical market
and provide a comparative instrument for the revised data.
RESULTS: Under the new data, the pharmaceutical market bears
two signiﬁcant changes: a) private pharmaceutical expenditure
accounts for 47.5% of total expenditure—against 22% which
was the case before the revision, and b) data on the demand side
appear to exceed supply-side data—the latter including parallel
exports. The disproportional rise in pharmaceutical expenditure
(58% on average for the years 2000–2005) led to an increase in
pharmaceuticals’ share to both health care expenditure and GDP.
Moreover, the increase was totally attributable to a shift in
private pharmaceutical expenditure—which was tripled- whereas
public expenditure remained at the before-the-revision levels.
However, such an increase contravenes both the fact that phar-
maceuticals in Greece are mainly reimbursed by Social Insurance
and the fact that the pharmaceutical market is heavily regulated
and—in general—“hidden economy” phenomena do not exist.
Furthermore, the increase is not supported by the results of the
2005 Household Budget Survey. CONCLUSION: The revised
data raise questions on the relationship of public-private phar-
maceutical expenditure and supply-demand market data, and
entail the risk of leading to irrational decision making for both
policy makers and pharmaceutical companies.
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OBJECTIVES: This study was conducted to clarify the relation-
ship between lifestyle-related diseases and medical expenses after
10 years of metabolic syndrome. METHODS: The subjects of
analysis were 2165 people who were randomly selected from a
population insured by the government-managed health insur-
ance. The test results of 1993 were used to divide the subjects of
analysis into the following 4 groups, and the diseases and
medical expenses of each group were examined for 2003. Group
1 had no abnormality in any of the four test RESULTS: BMI,
blood pressure, lipid levels, and glucose metabolism. Group 2
was not obese but had abnormality in one or more of the other
three tested categories. Group 3 was only obese or obese and had
abnormality in one of the other three tested categories. Group 4
had metabolic syndrome. In this study, the lifestyle-related
diseases were diabetes, hypertension, hyperlipidemia, cerebro-
vascular disease, and ischemic heart disease. RESULTS: The risk
of each lifestyle-related disease was examined by odds ratio
adjusted by sex and age in comparing Groups 2, 3, and 4 with
Group 1. The odds ratios of Groups 2, 3, and 4 were higher than
that of Group 1. In Group 4, there were signiﬁcant differences in
all diseases. Analysis of covariance adjusted for sex and age was
performed, and medical expenses were compared between each
group. As a result, the total amount of annual medical expenses
in 2003 was 52,470 yen for Group 1, 82,120 yen for Group 2,
72,720 yen for Group 3, and 109,660 yen for Group 4. The
medical expenses were signiﬁcantly higher in Group 4 compared
with Group 1. CONCLUSION: The risks of lifestyle-related
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